Douglas, M.D., Simon Finfer, F.R.C.P.D., John C. Marshall, M.D., Andrew Rhodes, M.D., Antonio Artigas, M.D., Ph.D., Didier Payen, M.D., Ph.D., Jyrki Tenhunen, M.D., Ph.D., Hussein R. Al-Khalidi, Ph.D., Vivian Thompson, M.P.H., Jonathan Janes, M.B., B.Ch., William L. Macias, M.D., Ph.D., Burkhard Vangerow, M.D., and Mark D. Williams, M.D. For the PROWESS-SHOCK Study Group: Drotrecogin Alfa in Adults with Septic Shock Recombinant human being activated protein C, or drotrecogin alfa , was approved for the treating severe sepsis in 2001 based on the Prospective Recombinant Individual Activated Protein C Worldwide Evaluation in Severe Sepsis study,1 a phase 3 international, randomized, controlled trial that was stopped early for efficacy after the enrollment of 1690 patients with severe sepsis.Findings from the study were published in the journal Clinical Infectious Illnesses recently. Young children will be the major reason why viruses are more common in large families. Kids younger than 5 experienced at least one virus detected in their noses for half the year, which was as often as teenagers and adults twice. When infected, small children had been 1.5 times much more likely to have symptoms, including severe ones such as wheezing and fever, the study said. ‘This study assists us to understand what is normal in young children, and can help us determine when illness should be a cause for concern,’ Byington stated.